CPRX Catalyst Pharmaceuticals Inc.

4.08
+0.01  (+0%)
Previous Close 4.07
Open 4.1
Price To Book 8.16
Market Cap 419,645,369
Shares 102,854,257
Volume 600,877
Short Ratio
Av. Daily Volume 2,579,974

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 1H 2020.
Firdapse
Spinal Muscular Atrophy (SMA) Type 3
Phase 3 data due 2H 2019.
Firdapse
MuSK-antibody positive myasthenia gravis (MuSK-MG)
Phase 3 data due 2H 2019.
Firdapse
Congenital Myasthenic Syndromes (CMS)
FDA approval announced November 28, 2018.
Firdapse
Lambert-Easton Myasthenic Syndrome (LEMS)

Latest News

  1. Do Directors Own Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares?
  2. Do Options Traders Know Something About Catalyst (CPRX) Stock We Don't?
  3. Catalyst Pharma Focuses on Firdapse Launch & Label Expansion
  4. Explosive Stocks Under $10
  5. Here is What Hedge Funds Think About Catalyst Pharmaceuticals, Inc. (CPRX)
  6. UPDATE 2-Catalyst Pharma sues FDA over approval of cheaper rival drug
  7. Catalyst (CPRX) Up 14.1% Since Last Earnings Report: Can It Continue?
  8. Catalyst Pharmaceuticals Files Federal Lawsuit Against U.S. Food and Drug Administration
  9. Catalyst Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference
  10. Catalyst Pharmaceuticals Announces Expansion of Firdapse License to Include Japan
  11. Edited Transcript of CPRX earnings conference call or presentation 13-May-19 12:30pm GMT
  12. Catalyst Pharmaceuticals settles patent dispute with Northwestern University
  13. Catalyst Pharma (CPRX) Rides on Successful Launch of Firdapse
  14. 5 Biotech Stocks to Watch in the Second Half of 2019
  15. Are These 2 Beaten-Down Biotech Stocks Worth the Risk?
  16. Catalyst (CPRX) Q1 Loss Narrows, Firdapse Off to a Good Start
  17. Implied Volatility Surging for Catalyst Pharmaceuticals (CPRX) Stock Options
  18. Catalyst Pharmaceuticals Posts Strong Q1 Sales for Firdapse
  19. Why Catalyst Pharmaceuticals Briefly Spiked Today
  20. Catalyst Pharmaceuticals Inc (CPRX) Q1 2019 Earnings Call Transcript